



Contractor Details	Type/ size of legal entity	Place of performance of contract activities	Logo
<p><u>Main contractor</u></p> <p>Name legal entity fragmentiX Storage Solutions GmbH</p> <p>Address legal entity IST Austria Technology Park, Plöcking 1, 3400 Klosterneuburg • Austria</p> <p>Contact person Andreas Paser tel.: +43 2243 24203 100 mobile: +43 677 64211 797 andreas.paser@fragmentix.com</p> <p>Roles and responsibilities:</p> <ul style="list-style-type: none"> project management: Christoph Pacher christoph.pacher@fragmentix.com administrative tasks: Svetlana Leonova svetlana.leonova@fragmentix.com legally authorised to act on behalf of the company: Werner Strasser ws@fragmentix.com 	SME	<p>% of contract value allocated to main contractor: 25,5 %</p> <p>% of activities for the contract performed by the main contractor in EU Member States or countries associated with Horizon 2020: [100] %</p>	
<p><u>Other consortium member</u></p> <p>Name legal entity ID GmbH & Co. KGaA</p> <p>Address legal entity Platz vor dem Neuen Tor 2, 10115 Berlin, Germany</p> <p>Contact person Dr. André Sander +49 30 24626 0 a.sander@id-berlin.de</p> <p>Roles and responsibilities:</p> <ul style="list-style-type: none"> project management: Dr. André Sander, a.sander@id-berlin.de administrative tasks: Barbara Burkhardt b.burkhardt@id-berlin.de, Anja Smolle a.smolle@id-berlin.de legally authorised to act on behalf of the company: Dr. Daniel Diekmann d.diekmann@id-berlin.de 	SME	<p>% of contract value allocated to main contractor: 24,9 %</p> <p>% of activities for the contract performed by the main contractor in EU Member States or countries associated with Horizon 2020: [100] %</p>	

<p><u>Other consortium member</u></p> <p>Name legal entity Maxeler Technologies Ltd</p> <p>Address legal entity 3 Hammersmith Grove, London, United Kingdom</p> <p>Contact person Tobias Becker +44 7804 688858 tbecker@maxeler.com</p> <p>Roles and responsibilities:</p> <ul style="list-style-type: none"> • project management: Tobias Becker tbecker@maxeler.com • administrative tasks: Shantel Holmes shantel@maxeler.com • legally authorised to act on behalf of the company: Oskar Mencer mencer@maxeler.com 	SME	<p>% of contract value allocated to contractor: 24,3 %</p> <p>% of activities for the contract performed by contractor Maxeler Technologies Ltd in EU Member States or countries associated with Horizon 2020: [100] %</p>	 <p>MAXELER Technologies Maximum Performance Computing</p>
<p><u>Subcontractor</u></p> <p>Name legal entity Prime Force GmbH</p> <p>Address legal entity Jakob-Haringer-Str. 5 5020 Salzburg - Austria</p> <p>Contact person Thomas Pesendorfer +43 676 71 66660 thomas.pesendorfer@prime-force.com</p> <p>Roles and responsibilities:</p> <ul style="list-style-type: none"> • project management: Thomas Pesendorfer thomas.pesendorfer@prime-force.com • administrative tasks: Anna-Maria Stabauer-Wigger anna-maria.stabauer-wigger@prime-force.com • legally authorised to act on behalf of the company: Andreas Pesendorfer andreas.pesendorfer@prime-force.com 	SME	<p>% of contract value allocated to subcontractor: 25,3 %</p> <p>% of activities for the contract performed by subcontractor in EU Member States or countries associated with Horizon 2020: [100] %</p>	 <p>PRIME FORCE SOLUTIONS YOU TRUST - EXPERTS YOU LOVE</p>
<p>Project abstract</p> <p>TDE4NGS has developed the design of a novel, innovative solution that will bring the treatment of cancer to the next level. Each patient will benefit from personalized medicine which is based on analysing the patient's genetic data and the latest results from medical and pharmaceutical research. Consequently, drug intolerances will be strongly decreased and the search for medication that fits to the patient's conditions will be faster. The patient can leave the hospital earlier and has a better chance of survival. The clinical effort and costs of the treatment will decrease at the same time.</p> <p>The result of the analysis will be immediately available for clinicians in the form of well-structured, detailed reports which show all relevant information. Patients will get easy-to-comprehend reports that are available through a web-service, and on apps for mobile devices. In our solution the patient's data is well protected against data leakage and data loss using unique secret sharing technologies which remove the need to trust a single data storage provider.</p>			



Previous EU funding

Is the project based on / a continuation of R&D activities that were previously funded by the EU?: No



Project funded by the EU Horizon 2020 Programme

